Virtuoso Optoelectronics turns profitable YoY, but ~half the PAT is a one-off tax credit
revenue +81% · margins expanding
₹177.08 Cr
+81% YoY
₹2.69 Cr
1.51%
+0.7pp YoY
₹0.78
Consolidated revenue came in at Rs177.08 Cr, up ~81% YoY from a loss-making Rs97.84 Cr base in Q2 FY26, with consolidated PAT of Rs2.69 Cr (attributable Rs2.61 Cr, EPS Rs0.78) against a Rs3.88 Cr loss a year ago −a YoY turnaround. Standalone mirrors it: revenue Rs156.62 Cr (+61% YoY) and PAT Rs1.83 Cr versus a Rs3.31 Cr standalone loss a year earlier. Sequentially both lines pull back sharply −consolidated revenue down 53% and PAT down 70% versus Q1 FY27's Rs375.88 Cr / Rs9.05 Cr −but Virtuoso makes air conditioners, water dispensers and deep freezers, and Q1 (Apr-Jun) is the peak summer selling season while Q2 (Jul-Sep) is structurally the weakest quarter; the QoQ drop reads as seasonal, not a deterioration in the underlying business.
Q2 FY-2027 vs prior quarters
Margins improved YoY (consolidated NPM -3.94% a year ago to +1.51% now) but compressed QoQ from Q1's 2.40%, while OPM held near 11.8% versus ~9.3% in Q1 and ~11.1% a year ago. Importantly, a large share of this quarter's reported profit is a one-off: both statements booked a net tax credit rather than an expense, because the company adopted the lower effective ~25.168% tax rate under Section 115BAA for the half-year, with Q1's shortfall versus the old 29.12% rate caught up in this quarter. Strip that out and adjusted PAT is closer to Rs0.54 Cr standalone / Rs1.40 Cr consolidated −still a swing from last year's loss, but a far thinner one than the headline Rs1.83 Cr / Rs2.69 Cr suggests.
The stock went into the print at ₹511.65, down 2.8% over the past month of trading.
FY27: maintain 35-40% revenue growth (vs 825 Cr base), 9-10% EBITDA margins, 2.5-3% NPM. Peak capacity ₹3,500-4,000 Cr post-expansion (~12-24 months). CapEx ₹80-100 Cr this year.
— This quarter: beat
Management's Q1 FY27 call guided FY27 revenue growth of 35-40% off an ~Rs825 Cr FY26 base (confirmed at Rs823.6 Cr actual) with 9-10% EBITDA margin and 2.5-3% NPM. H1 FY27 consolidated revenue of Rs552.96 Cr is running +82.8% YoY −well ahead of that growth guidance −and H1 EBITDA margin of ~10.1% is in line, but H1 NPM of ~2.1% is tracking a touch below the guided floor as finance costs (H1 consolidated Rs22.01 Cr, +41.7% YoY) and depreciation (Rs19.11 Cr) from the capacity build-out weigh on the bottom line even as EBITDA holds up. No sell-side consensus specific to this quarter turned up in search, so the street comparison is unknown, and no company press release was available to cross-check management's own framing. Post-period, the company completed an Rs85 Cr preferential allotment (16.9 lakh shares, Oct 15, 2026) and signed a non-binding Rs1,050 Cr investment MoU with the Maharashtra government (Oct 4, 2026), both consistent with the guided ramp to Rs3,500-4,000 Cr peak capacity over 12-24 months −though promoters have said they won't subscribe to the equity issue (EGM update, Oct 6, 2026).
W1
Whether the one-off tax credit reverses in Q3 FY27 −a return to a ~25% effective tax rate would pull PAT back toward the ~Rs1.40 Cr adjusted run-rate seen this quarter.
W2
H2 FY27 NPM trajectory versus management's guided 2.5-3% band as finance costs (Rs22.01 Cr in H1, borrowings up to Rs471.51 Cr from Rs276.53 Cr at FY26-end) and depreciation from the capacity ramp continue to rise.
W3
Progress on the Rs1,050 Cr Maharashtra MoU and utilisation of the Rs85 Cr equity raise (proceeds plan revised Sept 21, 2026) toward the guided Rs3,500-4,000 Cr peak capacity over the next 12-24 months.
Figures are in Rs. Lakhs in the source, converted /100 to Cr; standalone and consolidated both tie out (totalIncome = revenue+otherIncome; PBT-tax=PAT). Tax is a NET CREDIT in both statements (standalone -Rs1.11 Cr, consolidated -Rs0.82 Cr) from a deferred-tax regime catch-up (switch to Sec 115BAA ~25.168% effective rate, with Q1's old-regime (29.12%) difference booked in Q2) −stripping it, adjusted PAT is ~Rs0.54 Cr standalone / ~Rs1.40 Cr consolidated, roughly half the reported figure. Also: the supplied DB year-ago-quarter context (revenue Rs301.02 Cr, PAT +Rs2.54 Cr) does not match this filing's own 30.09.2025 comparative column (consolidated revenue Rs97.84 Cr, loss Rs3.88 Cr) or independent sources (FY26 full-year revenue Rs823.6 Cr, PAT Rs15.03 Cr) −used the filing's own comparative column for YoY math and flagged the DB figures as likely stale/mismatched.
H1 strength masks Q2 seasonal weakness; margins below guidance
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
H1 delivery strong; Q2 miss on revenue and margins. Prior 35-40% FY27 growth now unclear if achievable; new 30%+ CAGR is multi-year, not specific.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
H1 growth of 78% YoY (₹534 Cr) and strong order book underscore demand recovery. However, Q2 revenue collapsed 41% YoY (₹177 Cr) and NPM at 1.5% falls far short of 2.5-3% guidance, signalling execution and margin challenges. Management's shift to long-term 30%+ CAGR (vs prior 35-40% FY27) hints at cautious reset. Key risk: sequential deterioration suggests H2 momentum may be weaker than the bullish tone suggests.
₹177.1 Cr
Revenue · −41.2% YoY₹2.7 Cr
Reported PAT · +5.7% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
H1 delivered strong 78% YoY revenue growth (₹534 Cr vs ₹300 Cr)
METH1 FY27 ₹534 Cr standalone, H1 FY26 ₹300 Cr; Q2 FY27 ₹177.1 Cr down 41% YoY; Q1 FY27 ≈ ₹357 Cr implied
Order book looks very encouraging; 70-80% capacity utilization in H2
PartialQ2 was lean/seasonal; management attributes Q2 weakness to seasonality not demand; H2 demand claim not yet evidenced
EBITDA margins 9-10% range maintained
METQ2 OPM 11.2% (within range if comparable to EBITDA); H1 EBITDA growth 60% YoY aligns with margin stability claim
NPM striving towards 3%, with improvement from lower interest costs
OVERSTATEDQ2 NPM 1.5%, well below 2.5-3% prior guidance; Q2 attributable to seasonality and interest; PAT grew only 5.7% YoY despite much higher capacity
Capacity expansions on track; EMS operational in 45 days, AC indoor 70% done by December
METManagement confirmed timelines; no contradictory evidence in delivered result; expansion plan credible
Earnings quality
What changed since the last call
Growth guidance reset
DowngradePrior FY27 target 35-40% growth; now 30%+ CAGR (longer-term, less specific). Implies FY27 growth may fall short of 35%.
NPM trajectory delayed
DowngradePrior target 2.5-3% NPM; Q2 delivered 1.5%, deferred improvement to future quarters vs expected near-term.
Capacity expansion scope confirmed
NeutralEMS, AC, compressor expansions proceeding on track; no scope reduction or acceleration vs prior call.
Customer additions in AC
UpgradeAdded 3 new Tier 1/2 customers in AC in addition to anchor customer; was not detailed prior.
The Q&A
Analysts pressed on compressor unit economics (unit cost ₹1,400-1,500 vs smaller players), margin trajectory, and debt refinancing. Management was direct on most points (70% utilization, 40-60% outsourcing mix maintained) but deflected on: (a) specific customer names, (b) Nasik Phase 2 revenue, (c) exact NPM improvement timeline. Overall tone was confident but slightly defensive on margin questions.
Outsourcing mix — Shreyansh Jain, Unknown
Answered40-60% outsourcing mix maintained as company guideline. Industry trending towards outsourcing; we benefit by capping ourselves.
Compressor advantage — Piyush Jain, Unknown
AnsweredWe are only OEM/ODM supplying compressors; competing with imports on cost. Margins lower than AC/EMS now; expect improvement as backward integration (assembly) and imports reduce.
Debt management — Kunal Tokas, Unknown
AnsweredPlan to refinance ₹150 Cr OCD (bridge capital) to bank debt. Target debt-equity <1. Bank borrowing at 8.25-8.4% cost.
AC capacity utilization — Kunal Tokas, Unknown
PartialOrder book ramp-up + new customer additions. Hands full now; no capacity for new customers until expanded.
Nasik Phase 2 revenue — Hemant Soni, Unknown
DodgedComponent (Sanand/Chennai) is <5% of revenue. Refrain from giving specific estimate; will grow 30-35% over 5-year block.
EMS facility utilization — Hemant Soni, Unknown
AnsweredDesigned for captive first, external sales to follow. 70% of added capacity for captive; expandable for external.
CapEx completion timeline — Shreya Bajaj, Unknown
AnsweredNo further CapEx needed for peak revenue. Current ₹80-100 Cr FY27 CapEx sufficient; most tied up or spent. Balance of work matter of execution.
Inventory management — Shreyansh Jain, Unknown
AnsweredYes, mostly. Built for seasonal RAC demand (Oct onwards); will normalize as season progresses.
Freezer demand softness — Rajas Joshi, Unknown
PartialDemand strong; Q2 lean seasonally. Order book strong for Q3-Q4. Pass-through to brands ongoing; price stable last 6 months; pass-through slow but progressing.
AC capacity utilization — Rishabh Agrawal, Unknown
AnsweredCurrent 1M. IDU expansion to 15 lakh capacity; 70% enhancement done, 15 lakh/1.5M/1.6M capacity peak target; Q1 FY28 with 10 lakh base.
Guidance
FY27: 30%+ revenue CAGR (long-term), from ₹825 Cr base prior
MediumFramed as multi-year CAGR, not FY27-specific. H1 at 78% growth suggests FY27 will exceed 30% if H2 remains strong; but Q2 weakness suggests H2 may disappoint.
EBITDA margins 9-10% range; maintain consistency
HighQ2 OPM 11.2% within range; H1 EBITDA 56 Cr with 77% growth supports margin stability claim.
NPM: striving closer to 3% (vs 2.5-3% prior); deferred improvement
LowQ2 NPM 1.5%, well below target. Mgmt defers improvement to future quarters due to seasonality, interest costs, and working capital not yet optimized.
FY27 total CapEx ₹80-100 Cr (₹20-25 Cr product CapEx in refrigeration)
HighNo further CapEx needed; current plan sufficient to reach peak capacity. Most already spent or committed.
Risks the call surfaced
Execution risk
HighEMS (45 days), AC indoor (70% done, Dec target), compressor (end FY27 target), deep freezer expansion all in flight. Delays would undermine growth guidance.
Seasonality / demand risk
HighQ2 revenue -41% YoY (₹177 Cr vs ~₹301 Cr prior year). Attributed to seasonality, but magnitude steep. If H2 demand is softer than order book suggests, FY27 growth target misses.
Margin pressure
HighQ2 NPM 1.5% vs 2.5-3% guidance. Mgmt attributes to seasonality and interest; improvement deferred. If interest cost remains high or working capital doesn't improve, NPM stays depressed.
Competitive / pricing risk
MediumCompressors are new, competing with imported Chinese units. Mgmt expects margins to improve via backward integration (assembly) and as imports reduce. But timing and magnitude uncertain.
Customer concentration
MediumAnchor customer accounts for 40-50% of AC revenue. Loss or reduced offtake would significantly impact segment.
Management
Score 6/10. Mostly clear on numbers (H1 78% growth, EBITDA 9-10% guidance, debt ₹400 Cr). Deflected on specific customer names, Nasik Phase 2 revenue, and exact NPM timeline. Candid on challenges (Q2 lean, compressor margins, interest cost drag). H1 FY27 delivered 78% YoY growth (₹534 Cr) vs ₹300 Cr prior, hitting prior growth claims. Capacity expansions tracking schedule. But Q2 revenue miss (-41% YoY) and PAT growth only 5.7% YoY suggest execution is uneven (strong Q1, weak Q2).
1 · Q3-Q4 FY27
Seasonal demand upturn; order book monetization expected
2 · Dec 2026
AC indoor unit capacity expansion (targeting) + EMS facility live
3 · Q4 FY27 / Q1 FY28
Compressor capacity expansion to 6M units; backward integration in IDU/ODU begins
Key risk: sequential deterioration suggests H2 momentum may be weaker than the bullish tone suggests.